Clinical Updates in the Management of Patients with Rheumatologic Diseases During the COVID-19 Pandemic


Program Dates: August 24th, 2020 - August 23th, 2021
Credits: 1.0 AMA PRA Category 1 Credit™


Clinical Updates in the Management of Patients with Rheumatologic Diseases During the COVID-19 Pandemic

Program Overview

This CME activity will highlight the clinical updates in the management of patients with rheumatologic disease during the COVID-19 pandemic. The expert faculty, led by Dr. Kelly Weselman, will review strategies for optimizing treatment plans utilizing the latest American College of Rheumatology (ACR) guidelines for the care of patients with rheumatic disease during the COVID-19 pandemic. The faculty will then analyze the science and clinical trial data for treating patients on immunosuppressive therapies to maintain efficacy and safety during COVID-19. Finally, a review of the current options for virtual healthcare delivery, including telemedicine, to maintain standards of care and adherence to treatment will be discussed. Upon completion of this educational program, clinicians will gain better insight into how to manage patients with rheumatologic disease during the COVID-19 pandemic.

Target Audience

Rheumatologists and other healthcare professionals who are involved in the care and treatment of patients with rheumatological conditions

Agenda

I. ACR Guidelines for the Optimal Management of Patients with Rheumatic Diseases During the COVID-19 Pandemic
II. A Scientific Update on Clinical Trial Data for Therapeutic Options to Treat Patients with Rheumatic Disease in the COVID-19 Era
III. Practice Strategies for the Delivery of Virtual Healthcare During and After a Healthcare Crisis

Learning Objectives

  1. Review strategies for optimizing treatment plans utilizing the latest ACR guidelines for the care of patients with rheumatic diseases during the COVID-19 pandemic.
  2. Analyze the science and clinical trial data for treating patients on immunosuppressive therapies to maintain efficacy and safety during COVID-19.
  3. Examine the current options for virtual healthcare delivery, including telemedicine, to maintain standards of care and adherence to treatment.

Faculty

Kelly Weselman, MD
Wellstar Medical Group
Atlanta, GA

 

 

 

Sean M. Fahey, MD
Piedmont HealthCare
Mooresville, NC

 

 

 

Christopher R. Phillips, MD
Paducah Rheumatology
Paducah, KY

 

 

Disclosures of Conflict of Interest

It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:

Faculty Relationship Identified With:
Kelly Weselman, MD Nothing to disclose
Sean M. Fahey, MD Nothing to disclose
Christopher R. Phillips, MD Nothing to disclose

Planners and Peer Reviewers

Timothy Hayes, MD, PhD; Kim Cheramie, MSN, RN-BC; Nicole Brestowski and Chelsey Benedek hereby state that they or their spouse/life partner do not have any financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.

Accreditation Statement

In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. This activity was planned by and for the healthcare team.

Credit Designation Statements

AcademicCME designates this live material for a maximum of 1.0 AMA PRA Category 1 CreditTM

Financial Support

This activity has been supported by an independent educational grant from Eli Lilly and Company.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and Eli Lilly and Company do not recommend the use of any agent outside of the labeled indications.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Method of Participation

In order to claim credit, participants must complete the following:

  1. Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
  2. Complete the Pre-Activity Questions
  3. Read or Review the activity content.
  4. Complete the Post-Activity Test Questions and Evaluation.
  5. Learners who receive a grade of 70% or better on the Post-Activity Test Questions and complete the Evaluation will receive appropriate credit as indicated (CME, CNE, and/or CPE credit).
  • CPE credit will be posted to the learner’s CPE Monitor profile within 60 days of completion.
  • CME and CNE credit will be issued appropriate certificate of completion.
  • Others may request a “certificate of completion”.
  1. Learners should claim only the credit commensurate with the extent of their participation in the activity.

CE Inquiries/Special Needs

For all CE inquiries or special needs, please contact [email protected].

BUTTON

Provided by: AcademicCME-web